



## ***Clinical Criteria* updates**

**Summary:** On August 21, 2020, November 20, 2020, and June 24, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield Healthcare Solutions. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or need additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (\*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

**Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.**

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
March 15, 2022	*ING-CC-0201	Rybrevant (amivantamab-vmjm)	New
March 15, 2022	*ING-CC-0042	Monoclonal Antibodies to Interleukin-17	Revised
March 15, 2022	*ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
March 15, 2022	ING-CC-0125	Opdivo (nivolumab)	Revised
March 15, 2022	ING-CC-0124	Keytruda (pembrolizumab)	Revised
March 15, 2022	*ING-CC-0102	GnRH Analogs for Oncologic Indications	Revised
March 15, 2022	ING-CC-0076	Nulojix (belatacept)	Revised
March 15, 2022	*ING-CC-0077	Palynziq (pegvaliase-pqpz)	Revised
March 15, 2022	ING-CC-0067	Prostacyclin Infusion and Inhalation Therapy	Revised
March 15, 2022	*ING-CC-0174	Kesimpta (ofatumumab)	Revised
March 15, 2022	*ING-CC-0182	Agents for Iron Deficiency Anemia	Revised

<https://providers.anthem.com/nv>